Compound News and Research

RSS

Study pinpoints compounds that repress cancer gene’s activity

A research team pursuing one of the most commonly altered genes in cancer has laid a critical foundation for understanding this gene that could point the way toward developing drugs against it. A recent study of cancer genetics pointed to the gene MCL1, which encodes a protein that helps keep cells alive

17 Apr 2012

Florbetaben PET scan reliably identifies beta-Amyloid in the brain

Piramal Imaging SA, a newly formed subsidiary of Piramal Healthcare Limited, announced positive first results from a Phase III study that showed that PET imaging with florbetaben reliably detects beta-Amyloid in the brain during life with great accuracy and thus shows value as a potential tool to aid in the diagnosis and assessment of Alzheimer's disease.

16 Apr 2012

The key to treating AML may lie within FTL3 gene mutations

The key to treating one of the most common types of human leukemia may lie within mutations in a gene called FLT3, according to new research led by physician-scientists at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center.

16 Apr 2012

DNDi, AstraZeneca enter collaboration on drug-compound screening for NTDs

AstraZeneca and the Drugs for Neglected Diseases initiative (DNDi) today announce an agreement to collaborate on drug-compound screening for leishmaniasis, Chagas disease, and sleeping sickness, three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.

12 Apr 2012

New compound reverses major symptoms associated with FXS

A recent study finds that a new compound reverses many of the major symptoms associated with Fragile X syndrome (FXS), the most common form of inherited intellectual disability and a leading cause of autism. The paper, published by Cell Press in the April 12 issue of the journal Neuron, describes the exciting observation that the FXS correction can occur in adult mice, after the symptoms of the condition have already been established.

12 Apr 2012

KineMed receives NIH RAID grant to advance FX-5A for heart disease

KineMed Inc. today announced its successful award of a Rapid Access to Intervention Development (RAID) peer-reviewed grant by the National Institute of Health to advance an HDL mimetic, designated FX-5A, designed to reverse atherosclerosis and heart disease.

12 Apr 2012

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

12 Apr 2012

FDA ‘ups’ safety warnings for blood clots on birth control pill labels

According to federal health regulators more information needs to be added to labels on a popular class of birth control pills that includes Bayer AG's Yaz and Yasmin, to show they may raise the risk of blood clots. A clot in blood vessels can prove fatal if it breaks loose and travels to the lungs, heart or brain.

11 Apr 2012

Siemens announces integrated imaging solution for detection of amyloid plaques

Siemens Healthcare is the first company worldwide to announce a complete integrated diagnostic imaging solution proposed for the detection of amyloid plaques — one of the necessary pathological features of Alzheimer's disease— in the living brain.

From Siemens Healthineers 11 Apr 2012

Walgreens declares quarterly dividend of 22.5 cents per share

The board of directors of Walgreen Co. today declared a regular quarterly dividend of 22.5 cents per share, a 28.6 percent increase over the year ago dividend. The dividend is payable June 12, 2012, to shareholders of record May 21, 2012.

10 Apr 2012

Stealth announces results from three Bendavia Phase I clinical trials for mitochondrial dysfunction

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative therapies for diseases with unmet medical needs, announced today the results from three Phase I clinical trials of Bendavia, a novel compound that targets the mitochondrion to treat mitochondrial dysfunction, including ischemia reperfusion and microvascular injury.

9 Apr 2012

USPTO issues Notice of Allowance for Sunshine Biopharma's anti-tumor compound patent application

Sunshine Biopharma Inc. is pleased to announce that it has recently received notification that the United States Patent and Trademark Office has issued a "Notice of Allowance" for the patent application covering its lead anti-tumor compound, Adva-27a. The allowed claims protect Adva-27a and extensively cover various formulations, derivatives and cancer applications.

9 Apr 2012

Novel anti-leukemia compound with little toxicity successfully treats zebrafish

A novel anti-leukemia compound with little toxicity successfully treated zebrafish with T-cell acute lymphoblastic leukemia (T-ALL), suggesting its potential to become a new highly targeted therapy for humans - even those resistant to conventional therapies - according to results from a study published online today in Blood, the Journal of the American Society of Hematology (ASH).

9 Apr 2012

KU researchers receive inventorship credit on NIH-owned Velcade patents

Pillsbury today announced that its clients, the University of Kansas and the University of Kansas Center for Research, Inc., a nonprofit corporation affiliated with KU, prevailed in a closely watched legal battle over cancer drug formulation patents after an arbitration panel ruled in KUCR's favor following years of litigation against the National Institutes of Health.

7 Apr 2012

USPTO issues patent to ChromaDex’s pterostilbene

The U.S. Patent and Trademark Office has granted patent #8,133,917 pertaining to the ingredient pterostilbene, which is licensed exclusively to ChromaDex Corp., an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, and marketer of BluScience, its new line of dietary supplements.

6 Apr 2012

Early-life bisphenol A exposure affects later-stage learning impairment

In testing the effects of the controversial chemical bisphenol A (BPA) on zebrafish, UWM scientist Daniel Weber found himself in familiar territory.

5 Apr 2012

Soy may effectively reduce menopausal hot flashes

In the most comprehensive study to date to examine the effects of soy on menopause, researchers have found that two daily servings of soy can reduce the frequency and severity of hot flashes by up to 26 percent, compared to a placebo.

5 Apr 2012

Piceatannol blocks preadipocytes’ ability to develop and grow

A compound found in red wine, grapes and other fruits, and similar in structure to resveratrol, is able to block cellular processes that allow fat cells to develop, opening a door to a potential method to control obesity, according to a Purdue University study.

5 Apr 2012

TL32711 compound targets key pathway in lymphoma

Scientists at Fox Chase Cancer Center in Philadelphia have come one step closer to developing the first treatment to target a key pathway in lymphoma. The new findings will be announced at the AACR Annual Meeting 2012 on Tuesday, April 3.

4 Apr 2012

Onyx announces results from regorafenib Phase 3 trial on GIST

Onyx Pharmaceuticals, Inc. today announced results from the Phase 3 trial GRID (GIST – Regorafenib in Progressive Disease) evaluating the investigational compound regorafenib (BAY 73-4506), a Bayer-owned compound, for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib.

3 Apr 2012